A
Alloy Therapeutics
Provides affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma
About Alloy Therapeutics
Alloy Therapeutics (alloytx.com) is a biotech startup that provides drug discovery services and technology platforms to the broader scientific community. The company operates in the biologics discovery market, serving small and medium-sized biotech firms. Its business model is centered around democratizing access to advanced biologics discovery services and technology platforms, which it offers through bespoke campaigns or licensing agreements.
Read full description
Alloy Therapeutics' primary revenue source is from the licensing of its technology platforms and the provision of its discovery services. The company is committed to reinvesting all of its revenue back into innovation, which allows it to continuously develop and acquire new technologies to enhance its offerings and make its clients more successful.
The company's offerings include the ATX-Gx™ Transgenic Mice Platform and the Keyway™ TCR Discovery, among others. These platforms are designed to help clients discover the best therapeutic antibodies for their specific therapeutic targets. In addition to antibodies, Alloy Therapeutics has expanded into adjacent biologic modalities, including genetic medicines, cell therapies, peptides, and delivery, to help its partners find the best therapeutics for diseases, regardless of format.
In summary, Alloy Therapeutics is a biotech startup that offers cutting-edge biologics discovery services and technology platforms to small and medium-sized biotech firms, with a commitment to continuous innovation and client success.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Lexington, United States
- Employees
- 138
- Open positions
- 10
- Dealroom signal
- 76.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Verified Unicorns and $1B Exits, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 10 companies, latest Oct 2025
- Capital deployed
- $108M
- Preferred round
- SEED
Latest news
Press, funding announcements and product moves mentioning Alloy Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Apr 2026 | $40M | $1B | Thiel Capital · JIC Venture Growth Investments · Ulysses Diversified Holdings · Founders Fund | ↗ |
| SERIES DOther financing | Oct 2022 | $42M | $375M | Founders Fund · Presight Capital · 8VC · Thiel Capital | ↗ |
Growth signals
Latest recorded traffic for Alloy Therapeutics is 13K monthly website visits, up 0% over the last three months. Alloy Therapeutics's team grew 3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
SpannerwerksSeattle, United StatesConsulting for drug and biologic development commercialization
→
Wheeler BioOklahoma City, United StatesBy bringing together biologics drug innovators, discovery CROs, and CDMOs accelerating the translation of therapeutic innovation to clinical impact
$140Mvaluation
Vernal BiosciencesColchester, United StatesManufacturer of high purity mRNA for research and clinical use
$105Mvaluation
Tegmine TherapeuticsSan Francisco, United States
→
Mytide TherapeuticsBoston, United StatesManufacturing custom peptides for researchers
$28Mvaluation
DeepCDR BiologicsBasel, SwitzerlandAccelerating antibody discovery & engineering with deep learning
$160Kvaluation
Voro Therapeuticsoperational
→
Aldebaran TherapeuticsWaltham, United StatesPrecision ocular medicines using antisense oligonucleotide technology
$3.2Mvaluation
Aakha BiologicsoperationalWe utilize multiple advanced antibody discovery platforms to enable experienced drug hunters to go efficiently from concept through the IND enabling stage
→
Broadwing BioSouth San Francisco, United StatesEnvisioning an end to blindness
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later12 investors entered at this stage
8VC
Alexandria Venture Investments
Gaingels- UHUlysses Diversified Holdings
Founders Fund
Peter Thiel
Presight Capital
Mubadala Capital- LBLuma Bio-IT
Thiel Capital
JIC Venture Growth Investments
Echo Capital
Other known investors1 additional known investor
ETH Zurich
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alloy Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alloy Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.